11/19
01:29 pm
cing
Cingulate (NASDAQ:CING) had its price target lowered by analysts at Roth Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Cingulate (NASDAQ:CING) had its price target lowered by analysts at Roth Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
11/17
05:35 pm
cing
CING: Third Quarter Results [Yahoo! Finance]
Low
Report
CING: Third Quarter Results [Yahoo! Finance]
11/13
08:38 am
cing
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/13
08:00 am
cing
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
High
Report
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/10
08:40 am
cing
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 [Yahoo! Finance]
Low
Report
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 [Yahoo! Finance]
11/10
08:00 am
cing
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Medium
Report
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
10/28
08:00 am
cing
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
Medium
Report
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
10/23
04:45 pm
cing
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Medium
Report
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
10/15
02:24 pm
cing
Cingulate (NASDAQ:CING) had its price target raised by analysts at Roth Capital from $10.00 to $17.00. They now have a "buy" rating on the stock.
Medium
Report
Cingulate (NASDAQ:CING) had its price target raised by analysts at Roth Capital from $10.00 to $17.00. They now have a "buy" rating on the stock.
10/14
08:00 am
cing
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
Low
Report
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
9/17
08:45 am
cing
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
High
Report
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment